LivaNova PLC (LIVN)

Currency in USD
75.78
-2.36(-3.02%)
Closed·
75.780.00(0.00%)
·
LIVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
75.2878.18
52 wk Range
48.5785.76
Key Statistics
Prev. Close
75.78
Open
77.55
Day's Range
75.28-78.18
52 wk Range
48.57-85.76
Volume
932.46K
Average Volume (3m)
748.59K
1-Year Change
56.183%
Book Value / Share
24.13
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LIVN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
88.60
Upside
+16.92%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings downwards for the upcoming period

LivaNova PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 88.60
(+16.92% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy85.00+12.17%80.00MaintainAug 05, 2026
Needham
Buy93.00+22.72%81.00MaintainAug 05, 2026
Mizuho
Buy95.00+25.36%90.00MaintainJul 15, 2026
Baird
Buy95.00+25.36%76.00MaintainJul 14, 2026
Freedom Capital
Hold81.00+6.89%-New CoverageJun 30, 2026

LivaNova PLC SWOT Analysis


Cardio Innovation
LivaNova's Essenz heart-lung machine leads a "generational product cycle," poised to drive significant growth through 2027 in the cardiopulmonary market
Financial Pulse
Analysts project 6-7% organic growth, with potential to exceed in 2025. Price targets range from $56 to $80, suggesting upside potential
Pipeline Prospects
Explore LivaNova's diversification strategy with promising developments in sleep apnea and depression treatments, potentially opening new revenue streams
Market Challenges
Delve into LivaNova's navigation of mature franchises, regulatory hurdles, and legal uncertainties, balancing innovation against competitive pressures
Read full SWOT analysis

LivaNova PLC Earnings Call Summary for Q2/2026

  • LivaNova reported Q2 adjusted EPS of $1.26, beating estimates by 15.6%, with revenue of $390.6M exceeding forecasts by 2.64%.
  • Company raised FY2026 guidance: revenue growth to 8-9% from 7-8%, adjusted EPS to $4.30-$4.40, reflecting double-digit segment growth.
  • Cardiopulmonary revenue rose 10% to $222M; oxygenator market share expanded to 40% from 30%, supported by Thermo Fisher supply agreement.
  • Capital spending increased to $135M from $120M for capacity expansion; free cash flow guidance lowered to $140-160M from $160-180M.
  • OSA PMA supplement submission delayed to H2 2026-H1 2027; management cited verification work, not safety concerns, as cause for timeline shift.
Last Updated: 05/08/2026, 14:22
Read Full Transcript

Earnings

Latest Release
Aug 05, 2026
EPS / Forecast
1.26 / 1.09
Revenue / Forecast
390.6M / 380.57M
EPS Revisions
Last 90 days

LIVN Income Statement

Compare LIVN to Peers and Sector

Metrics to compare
LIVN
Peers
Sector
Relationship
P/E Ratio
22.1x19.7x−0.4x
PEG Ratio
0.120.150.00
Price/Book
3.2x3.9x2.6x
Price / LTM Sales
2.8x4.7x3.0x
Upside (Analyst Target)
20.7%45.5%50.7%
Fair Value Upside
Unlock11.4%7.2%Unlock

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
34.33M62.49%2.68B
Other Institutional Investors
29.49M37.51%2.30B
Public Companies & Retail Investors
0.000.00%0.00
Total
63.82M100.00%4.99B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.13.00%7,138,908557,870
PRIMECAP Management Company7.66%4,207,052328,760

People Also Watch

838.06
LITE
+1.43%
230.43
CRDO
+2.58%
1,258.58
SNDK
-6.81%
64.20
CNC
-4.16%
403.76
CIEN
-1.24%

FAQ

What Is the LivaNova PLC (LIVN) Stock Price Today?

The LivaNova PLC stock price today is 75.78 USD.

What Stock Exchange Does LivaNova PLC Trade On?

LivaNova PLC is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for LivaNova PLC?

The stock symbol for LivaNova PLC is "LIVN."

What Is the LivaNova PLC Market Cap?

As of today, LivaNova PLC market cap is 4.17B USD.

What Is LivaNova PLC's Earnings Per Share (TTM)?

The LivaNova PLC EPS (TTM) is 3.45.

When Is the Next LivaNova PLC Earnings Date?

LivaNova PLC will release its next earnings report on Nov 04, 2026.

From a Technical Analysis Perspective, Is LIVN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has LivaNova PLC Stock Split?

LivaNova PLC has split 0 times.

How Many Employees Does LivaNova PLC Have?

LivaNova PLC has 3300 employees.

What is the current trading status of LivaNova PLC (LIVN)?

As of Aug 07, 2026, LivaNova PLC (LIVN) is trading at a price of 75.78 USD, with a previous close of 75.78 USD. The stock has fluctuated within a day range of 75.28 USD to 78.18 USD, while its 52-week range spans from 48.57 USD to 85.76 USD.

What Is LivaNova PLC (LIVN) Price Target According to Analysts?

The average 12-month price target for LivaNova PLC is 88.60 USD, with a high estimate of 100 USD and a low estimate of 67 USD. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +16.92% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.